Dublin, Sept. 26, 2022 (GLOBE NEWSWIRE) -- The "Global Antibody Therapeutics Growth Opportunities" report has been added to ResearchAndMarkets.com's offering.
This research service offers an outlook of the global antibody therapeutics market for 2022 and beyond, highlighting emerging trends and growth opportunities.
As innovation takes center stage, the market is likely to witness remarkable growth in the near future, attributable to the focus on bi- and multi-specific antibodies, which has augmented investments by emerging start-ups in this space.
Moreover, the adoption of the antibody-drug co-development strategy by key market participants is rising; they use it to leverage technologically advanced drug discovery and development platforms, especially for non-standard antibody therapies, including antibody-drug conjugates.
Market growth is likely to be fueled by the growing utilization of cost-effective and efficient continuous manufacturing processes and single-use bioreactors for production, which will also reduce the time between development and commercialization. Favorable regulatory reforms in emerging Asian countries are encouraging the manufacture and introduction of monoclonal antibody-based biosimilars, aiming to reduce the cost-burden of originator antibody therapies.
The tailored approach used by manufacturers to improve the targeting efficiency of drug molecules toward multiple antigens is strengthening the pipeline portfolio of SMEs in the antibodies space and accelerating the pace of antibody drug development for cancer treatment.
Immuno-oncology remains a key focus area in the antibody therapeutics market, especially due to the emergence of highly target-specific antibody-drug conjugates and bispecific antibodies. Key manufacturers are striving to reduce in-house operations to leverage the capabilities of contract development and manufacturing organizations (CDMOs) with the aim of boosting innovation in the industry, which is likely to change the face of the market over the next 5 years.
Research Highlights
- Conventional and recombinant antibody therapeutics market size, including key segments, from 2022 to 2027
- Dynamics around product innovation and the reimbursement scenario
- Regulatory reforms and technological advancements driving value chain transformation
- Current and future R&D efforts and investment outlook
- Growth opportunities that market participants can focus on in the near
Key Topics Covered:
1. Strategic Imperatives
- Why is it Increasingly Difficult to Grow?
- The Strategic Imperative
- The Impact of the Top 3 Strategic Imperatives on the Antibody Therapeutics Industry
- Growth Opportunities Fuel the Growth Pipeline Engine
2. Growth Opportunity Analysis
- Scope of Analysis
- Segmentation and Definition
- Definitions by Technology Subtype
- Growth Drivers
- Growth Restraints
- Key Takeaways
3. Growth Environment
- Antibody Therapeutics - Pipeline Snapshot
- Pipeline Scenario of Late - stage Antibody Therapeutics
- Potential Therapy Areas
- Value Chain - Key Stakeholders
- Key Antibody Therapeutics Manufacturers
- Key Industry Trends by Region
- Key Industry Trends by Route of Administration
- Key Industry Trends - Antibody - Drug Conjugates
- Key Industry Trends - Technological Advancements
- Pricing Analysis of Antibody Therapeutics
- Factors Influencing the Pricing of Antibody Therapeutics
- Reimbursement Scenario for Antibody Therapeutics
- Reimbursement for Antibody Therapeutics - Regional Overview
- Notable Partnerships and Collaborations for Antibody Therapeutics
4. Revenue Forecast
- Growth Metrics
- Research Methodology
- Forecast Assumptions
- Revenue Forecast
- Revenue Forecast Analysis
- Revenue Forecast by Technology
- Revenue Forecast by Technology Discussion
- Competitive Environment
- Revenue Share Analysis
- Key ADC Developers to Watch in 2022
5. Growth Opportunity Universe
- Growth Opportunity 1 - Developing Multi - specific Antibodies for Immuno - oncology
- Growth Opportunity 2 - Collaborating with CDMOs and Platform Providers for the Further Development of ADCs
- Key Alliances in ADCs
- Growth Opportunity 3 - Expanding Accessibility to and Indications of Monoclonal Antibody Biosimilars
For more information about this report visit https://www.researchandmarkets.com/r/gpx0wm
